Researchers at Lancaster University have identified a type 2 diabetes drug that has shown potential benefit in the treatment of Alzheimer’s disease. The treatment combined three older diabetes drugs to create a “triple agonist”, that combines GLP-1, GIP and glucagon. The belief being that boosting levels of growth hormones will aid in protecting the brain
Eli Lilly has announced that it will offer its insulin medication, at a 40% discount for eligible patients when purchased through the Blink Health app or website. Patients most likely to save on their purchase of insulin are those with no insurance or are in the deductible phase of their high-deductible insurance plans.
Lilly is hoping to launch 20 new molecular entities in the 2014 to 2023 timeframe, backed up by two new indications or line extensions each year, throughout its core therapeutic categories of diabetes, immunology, oncology, neurodegeneration and pain.
Diabetes is a common lifelong condition that is currently affecting the health of many people in the UK. It is estimated that there is currently 1 in 16 people living with the disease either diagnosed or undiagnosed. Under normal circumstances the pancreas produces insulin, a hormone that allows glucose to enter cells to be used
Eli Lilly and Boehringer Ingelheim’s Jardiance has become the first diabetes drug to show a significant reduction in cardiovascular deaths in a dedicated outcomes study. According to data* from the 7,000-plus patient trial EMPA-REG OUTCOME, Jardiance (empagliflozin) cut the risk of cardiovascular death by 38% when added to standard of care in type II diabetics
A three year partnership between AstraZeneca (AZ) and French National Institute of Health and Medical Research (Inserm) is aiming to advance the understanding of biological mechanisms that come with the conditions. Based on the findings, they hope to develop new therapeutic approaches to type 2 diabetes and chronic kidney disease.
Novo Nordisk has confirmed that they are investing around 750 million kroner (roughly equivalent to $130 million) on new diabetes laboratories at the R&D campus in Måløv, Denmark. Construction of the new laboratories has already started and the new facility, to be named the Diabetes Research House, will open in early 2016. The Diabetes Research
Eli Lilly has announced the results of their head-to-head clinical study which demonstrates that their investigational GLP-1 glucagon-like peptide 1 receptor agonist, dulaglutide, is just as effective as Novo Nordisk’s Victoza, the market-leader in the area. The pharmaceutical company revealed the positive top-line results of the sixth clinical trial in their AWARD programme, whereby once-weekly
Johnson & Johnson (J&J) has announced that they have received regulatory approvals on both sides of the Atlantic for Olysio and Invokana. The US regulatory body, the Food and Drug Administration (FDA), approved Olysio (simeprevir) on Friday to treat chronic hepatitis C virus infection. The drug was co-developed with Sweden’s Medivir.